Catalent Breaks Ground at $112-Million Drug Product Manufacturing Facility

News
Article

Catalent recently held a groundbreaking ceremony at its Bloomington, Indiana pharmaceutical fill/finish site.

Catalent recently held a ground breaking ceremony at its Bloomington, Indiana site to mark the start of construction on a $112-million drug product manufacturing facility, which will increase fill/finish capacity at the site by 79,000 ft2. The facility will house a high-speed vial line, using both ready-to-use components and bulk filling; a high-speed flexible syringe/cartridge line; a fully automated vial inspection machine; and all associated services and support areas. Catalent Biologics plans to create up to 200 new jobs to support the increased production. Completion of both construction and recruitment are expected by the end of 2024.

Source: Catalent

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Related Content